RECENT PLACEMENT

Occam Places Aron Feingold as VP of Investor Relations & Corporate Communications at Geron

Occam Places Aron Feingold as VP of Investor Relations & Corporate Communications at Geron

Geron is a public, clinical stage biotech company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.

‍

In early 2022, Occam placed Aron Feingold (former Sangamo and Pfizer), as VP of Investor Relations & Corporate Communications, a role crucial to Geron at this point in its evolution, as it approaches potential registration and commercialization.

‍

Read more about Occam's work with Geron in our case study.

‍

Related Placements

  1. Daniel Delubac as COO & CTO at Chemify
  2. Sanjeev Luther as President and CEO of Eterna Therapeutics
  3. Shakti Narayan, JD, PhD as CEO for Oncology Biotech Accent Therapeutics
  4. David Moller as Chief Scientific Officer of Variant Bio
  5. Daphne Karydas Recruitment to the Board of Elicio
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.